GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (NAS:LQDA) » Definitions » Goodwill-to-Asset

Liquidia (Liquidia) Goodwill-to-Asset : 0.02 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Liquidia Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Liquidia's Goodwill for the quarter that ended in Mar. 2024 was $3.90 Mil. Liquidia's Total Assets for the quarter that ended in Mar. 2024 was $197.12 Mil. Therefore, Liquidia's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 was 0.02.


Liquidia Goodwill-to-Asset Historical Data

The historical data trend for Liquidia's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia Goodwill-to-Asset Chart

Liquidia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Goodwill-to-Asset
Get a 7-Day Free Trial - 0.04 0.04 0.03 0.03

Liquidia Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.04 0.03 0.02

Competitive Comparison of Liquidia's Goodwill-to-Asset

For the Biotechnology subindustry, Liquidia's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liquidia's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liquidia's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Liquidia's Goodwill-to-Asset falls into.



Liquidia Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Liquidia's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=3.9/118.332
=0.03

Liquidia's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Goodwill to Asset (Q: Mar. 2024 )=Goodwill/Total Assets
=3.9/197.116
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Liquidia  (NAS:LQDA) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Liquidia Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Liquidia's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Liquidia (Liquidia) Business Description

Traded in Other Exchanges
Address
419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.
Executives
Rajeev Saggar officer: Chief Medical Officer 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Jason Adair officer: V.P. Crp Dvlpmnt and Strtgy C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Roger Jeffs director
Caligan Partners Lp director, 10 percent owner, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Robert A Lippe officer: Chief Operations Officer C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Scott Moomaw officer: SVP, Commercial P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Michael Kaseta officer: Chief Financial Officer 7100 WEST CREDIT AVENUE, SUITE 101, MISSISSAUGA A6 L5N OE4
Russell Schundler officer: General Counsel P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Katherine Rielly-gauvin director 419 DAVIS DRIVE, MORRISVILLE NC 27560
Raman Singh director C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Joanna Horobin director 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Stephen M Bloch director 285 RIVERSIDE AVENUE, SUITE 250, WESTPORT CT 06880